The hematopoietic system: A new niche for the renin-angiotensin system

Nature Clinical Practice Cardiovascular Medicine

Volumn 3, Issue 2, 2006, Pages 80-85

  Hubert, Christine ^a   Savary, Katia ^a   Gasc, Jean Marie ^a   Corvol, Pierre ^a,b  

^a l'alimentation et l'Environnement   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Anemia; Angiotensin converting enzyme inhibitors; Angiotensin II receptor antagonist; Definitive hematopoiesis; Primitive hematopoiesis

Indexed keywords

AMLODIPINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ERYTHROPOIETIN; HEMOGLOBIN; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE; PERINDOPRIL; TELMISARTAN; VALSARTAN;

ANEMIA; BLOOD TOXICITY; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE ASSOCIATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; NONHUMAN; PANCYTOPENIA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINS; ANIMALS; CHICK EMBRYO; ERYTHROPOIETIN; HEMATOPOIESIS; HEMATOPOIETIC SYSTEM; HUMANS; MICE; OLIGOPEPTIDES; RENIN-ANGIOTENSIN SYSTEM;

EID: 32144448029     PISSN: 17434297     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpcardio0449     Document Type: Review

References (55)

1. Dzau VJ and Pratt RE (1986) Renin-angiotensin system: Biology, physiology and pharmacology. In Handbook of Experimental Cardiology, 1631-1661 (Eds Haber E et al.) New York: Raven
2. Dzau VJ et al. (2001) The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data. Am J Cardiol 88: 1L-20L
3. Dostal DE and Baker KM (1999) The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 85: 643-650
4. Haznedaroglu IC et al. (1996) A local renin-angiotensin system in the bone marrow. Med Hypotheses 46: 507-510
5. Griffing GT and Melby JC (1982) Enalapril (MK-421) and the white cell count and haematocrit. Lancet 1: 1361
6. Vlahakos DV et al. (1991) Enalapril-associated anemia in renal transplant recipients treated for hypertension. Am J Kidney Dis 17: 199-205
7. Vlahakos DV et al. (2003) Posttransplant erythrocytosis. Kidney Int 63: 1187-1194
8. Conlon PJ et al. (1996) Losartan in post-transplant erythrocytosis. Nephrol Dial Transplant 11: 2524-2525
9. Julian BA et al. (1998) Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 9: 1104-1108
10. Dahlof B et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359: 995-1003
11. Julius S et al. (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 363: 2022-2031
12. Cross MA and Enver T (1997) The lineage commitment of haemopoietic progenitor cells. Curr Opin Genet Dev 7: 609-613
13. Watt FM and Hogan BL (2000) Out of Eden: Stem cells and their niches. Science 287: 1427-1430
14. Barreda DR and Belosevic M (2001) Transcriptional regulation of hemopoiesis. Dev Comp Immunol 25: 763-789
15. Morrison SJ et al. (1997) Regulatory mechanisms in stem cell biology. Cell 88: 287-298
16. Tenen DG et al. (1997) Transcription factors, normal myeloid development, and leukemia. Blood 90: 489-519
17. Haznedaroglu IC and Ozturk MA (2003) Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system. Int J Biochem Cell Biol 35: 867-880
18. Vlahakos DV et al. (1995) Renin-angiotensin system stimulates erythropoietin secretion in chronic hemodialysis patients. Clin Nephrol 43: 53-59
19. Walter J (1993) Does captopril decrease the effect of human recombinant erythropoietin in haemodialysis patients? Nephrol Dial Transplant 8: 1428
20. Macdougall IC (1999) The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant 14: 1836-1841
21. Monpezat JP and Frindel E (1989) Further studies on the biological activities of the CFU-S inhibitory tetrapeptide AcSDKP.I. The precise point of the cell cycle sensitive to AcSDKP. Studies on the effect of AcSDKP on GM-CFC and on the possible involvement of T-lymphocytes in AcSDKP response. Exp Hematol 17: 1077-1080
22. Lenfant M et al. (1989) Inhibitor of hematopoietic pluripotent stem cell proliferation: Purification and determination of its structure. Proc Natl Acad Sci USA 86: 779-782
23. Robinson S et al. (1992) The mechanism of action of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) in the control of haematopoietic stem cell proliferation. Cell Prolif 25: 623-632
24. Rieger KJ et al. (1993) Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline. Biochem J 296: 373-378
25. Hubert C et al. (1991) Structure of the angiotensin I-converting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene. J Biol Chem 266: 15377-15383
26. Kumar RS et al. (1991) The mRNAs encoding the two angiotensin-converting isozymes are transcribed from the same gene by a tissue-specific choice of alternative transcription initiation sites. J Biol Chem 266: 3854-3862
27. Soubrier F et al. (1988) Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA 85: 9386-9390
28. Rousseau A et al. (1995) The hemoregulatory peptide N-Acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem 270: 3656-3661
29. Azizi M et al. (1996) Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator. J Clin Invest 97: 839-844
30. Struthers AD et al. (1999) Nonadherence with angiotensin-converting enzyme inhibitor therapy: A comparison of different ways of measuring it in patients with chronic heart failure. J Am Coll Cardiol 34: 2072-2077
31. Fuchs S et al. (2004) Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J Biol Chem 279: 15946-15953
32. Esther CR et al. (1996) Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 74: 953-965
33. Cole J et al. (2000) Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice. J Clin Invest 106: 1391-1398
34. Naito M et al. (2003) Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients. Am J Nephrol 23: 287-293
35. Mrug M et al. (1997) Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 100: 2310-2314
36. Rodgers KE et al. (2000) Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells 18: 287-294
37. Brunet de la Grange P et al. (2002) Angiotensin II that reduces the colony-forming ability of hematopoietic progenitors in serum free medium has an inverse effect in serum-supplemented medium. Stem Cells 20: 269-271.
38. + cells expansion in vitro [Chinese]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 11: 227-229
39. Caprioli A et al. (1998) Blood-borne seeding by hematopoietic and endothelial precursors from the aliantois. Proc Natl Acad Sci USA 95: 1641-1646
40. Ferrario CM (2002) Angiotensin I, angiotensin II and their biologically active peptides. J Hypertens 20: 805-807
41. Leung PS (2004) The peptide hormone angiotensin II: Its new functions in tissues and organs. Curr Protein Pept Sci 5: 267-273
42. Rodgers K et al. (2003) Effect of angiotensin II and angiotensin(1-7) on hematopoietic recovery after intravenous chemotherapy. Cancer Chemother Pharmacol 51: 97-106
43. Rodgers KE et al. (2002) Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemother Pharmacol 49: 403-411
44. Strawn WB et al. (2004) Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br J Haematol 126: 120-126
45. Richmond RS et al. (2004) Angiotensin II stimulates arachidonic acid release from bone marrow stromal cells. J Renin Angiotensin Aldosterone Syst 5: 176-182
46. Neubauer H et al. (1998) Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93: 397-409
47. Marrero MB et al. (1995) Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 375: 247-250
48. Haznedaroglu IC et al. (2000) A unifying hypothesis for the renin-angiotensin system and hematopoiesis: Sticking the pieces together with the JAK-STAT pathway. Med Hypotheses 54: 80-83
49. Lassila O et al. (1982) Erythropoiesis and lymphopoiesis in the chick yolk-sac-embryo chimeras: Contribution of yolk sac and intraembryonic stem cells. Blood 59: 377-381
50. Savary K et al. (2005) Role of the renin-angiotensin system in primitive erythropoiesis in the chick embryo. Blood 105: 103-110
51. Tavian M et al. (2005) The vascular wall as a source of stem cells. Ann NY Acad Sci 1044: 41-50
52. Rell K et al. (1994) Correction of posttransplant erythrocytosis with enalapril. Transplantation 57: 1059-1063
53. de Simone G et al. (1990) Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in apparently normal adults. Circulation 81: 107-117
54. Parker AN and Pragnell IB (1995) Inhibitors of haemopoiesis and their potential clinical relevance. Blood Rev 9: 226-233
55. Charrier S et al. (2004) Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells. Blood 104: 978-985